Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | |||
| Net Income | 19,411 | N/A | N/A |
| Depreciation Amortization | 603 | N/A | N/A |
| Accounts receivable | 334 | N/A | N/A |
| Accounts payable and accrued liabilities | -55 | N/A | N/A |
| Other Working Capital | -7,536 | N/A | N/A |
| Other Operating Activity | 2,399 | 0 | 0 |
| Operating Cash Flow | $15,156 | $N/A | $N/A |
| Cash Flows From Investing Activities | |||
| PPE Investments | -1,547 | N/A | N/A |
| Investing Cash Flow | $-1,547 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||
| Debt Issued | 4,082 | N/A | N/A |
| Debt Repayment | -1,310 | N/A | N/A |
| Common Stock Issued | 169 | N/A | N/A |
| Other Financing Activity | 119,666 | 0 | 0 |
| Financing Cash Flow | $122,607 | $N/A | $N/A |
| Exchange Rate Effect | -587 | N/A | N/A |
| Beginning Cash Position | 30,490 | N/A | N/A |
| End Cash Position | 166,119 | N/A | N/A |
| Net Cash Flow | $135,629 | $N/A | $N/A |
| Free Cash Flow | |||
| Operating Cash Flow | 15,156 | N/A | N/A |
| Capital Expenditure | -1,547 | N/A | N/A |
| Free Cash Flow | 13,609 | 0 | 0 |